Antimicrobial Stewardship and Prescribing Practice
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotics Use and Antimicrobial Stewardship".
Deadline for manuscript submissions: closed (30 March 2024) | Viewed by 30797
Special Issue Editor
Interests: antimicrobial stewardship; infectious diseases; microbiome; therapeutic monitoring; neurochemistry; neuropharmacology; neurodegenerative diseases; clinical pharmacy
Special Issue Information
Dear Colleagues,
Antimicrobial resistance is still a serious and growing problem in the treatment of severe infections. There are two main approaches to tackle this challenge: the development of novel substances which can bypass the resistance mechanisms, but also the continuous development of strategies to increase the adequate prescription of currently available antibiotics where they are needed. The last approach, i.e., antimicrobial stewardship strategies, is already well established in many countries and usually consists of a bundle of recommendations in order to improve the prescription practice and thus slow down the development of resistance. Among the recommendations communicated within antimicrobial stewardship programs or guidelines, the publication of local treatment guidelines and an antibiotics house list with concrete dosage recommendations are recommended for each hospital. This sounds like a clear and easy task but nevertheless requires teamwork among experts in practical reality and very often thorough consideration of advantages or disadvantages of different recommendations.
This Special Issue is meant to bring some new answers to the following questions: 1. Is there a rationale for the selection of antibiotics in special situations such as treatment of severe infections with abscess formation? 2. Should we use special dosage recommendations in distinct clinical circumstances that lead to altered antibiotic concentrations at the site of infection (e.g., special dosing recommendations for patients with altered kidney or liver function, renal replacement therapy or obesity)?
Invited are papers of any type (case reports, original articles describing the setup of a new local guideline, review articles) with a clear rationale and clear message for the colleagues.
Dr. Andreas A. Von Ameln-Mayerhofer
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.